Calabasas-based KYTHERA Biopharmaceuticals, a developer of biopharmaceuticals for the aesthetic medicine market, has filed for an IPO. According to the firm's S-1 filing, Kythera is looking to raise up to $86.25M on the NASDAQ Global Market as KYTH. The firm's offering is being underwritten by J.P. Morgan, Goldman, Sachs & Co., Leerink Swann, and Lazard Capital Markets. Kythera is venture backed by Versant Ventures, ARCH Ventures, Prospect Venture Partners, JAFCO, Fidelity, among others. The firm reported a net loss of $11.1M on license income of $12.98M in 2011. Kythera's products are used for fat reduction.
Top NewsThursday, May 17, 2012
Kythera Files For IPO